Abstract
Previously we have shown that deregulated expression of c-myc in M1 myeloid leukemic cells blocked IL-6-induced differentiation and its associated growth arrest; however, the cells proliferated at a significantly reduced rate compared to untreated cells. The basis for the increased doubling time of IL-6-treated M1myc cells was found to be due to the induction of a p53-independent apoptotic pathway. The apoptotic response was not completely penetrant; in the same population of cells both proliferation and apoptosis were continuously ongoing. Down-regulation of Bcl-2 was insufficient to account for the apoptotic response, since deregulated expression of Bcl-2 delayed, but did not block, the onset of apoptosis. Furthermore, our results indicated that the IL-6-induced partial hypophosphorylation of the retinoblastoma gene product (Rb), observed in M1myc cells, was not responsible for the apoptotic response. Finally, the findings in M1 cells were extended to myeloid cells derived from the bone marrow of wild type and p53-deficient mice, where the deregulated expression of c-myc was also shown to block terminal differentiation and induce apoptosis independent of p53. These findings provide new insights into how myc participates in the neoplastic process, and how additional mutations can promote more aggressive tumors.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Abdollahi A, Lord KA, Hoffman-Liebermann B and Liebermann DA . 1991a Cell Growth Differ 2: 401–407
Abdollahi A, Lord KA, Hoffman-Liebermann B and Liebermann DA . 1991b Oncogene 6: 165–167
Askew DS, Ashmun RA, Simmons BC and Cleveland JL . 1991 Oncogene 6: 1915–1922
Bissonnette RP, Echeverri F, Mahboubi A and Green DR . 1992 Nature 359: 552–554
Chao DT and Korsmeyer SJ . 1998 Annu Rev Immunol 16: 395–419
Eilers M . 1999 Mol Cells 9: 1–6
Evan GI and Littlewood TD . 1993 Curr Opin Genet Dev 3: 44–49
Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, Waters CM, Penn LZ and Hancock DC . 1992 Cell 69: 119–128
Facchini LM and Penn LZ . 1998 Faseb J 12: 633–651
Fanidi A, Harrington EA and Evan GI . 1992 Nature 359: 554–556
Freytag SO . 1988 Mol Cell Biol 8: 1614–1624
Graf T . 1992 Curr Opin Genet Dev 2: 249–255
Hawley RG . 1994 Ann N Y Acad Sci 716: 327–330
Hoffman B and Liebermann DA . 1998 Oncogene 17: 3351–3357
Hoffman-Liebermann B and Liebermann DA . 1991a Mol Cell Biol 11: 2375–2381
Hoffman-Liebermann B and Liebermann DA . 1991b Oncogene 6: 903–909
Hueber AO, Zornig M, Lyon D, Suda T, Nagata S and Evan GI . 1997 Science 278: 1305–1309
Kagaya S, Kitanaka C, Noguchi K, Mochizuki T, Sugiyama A, Asai A, Yasuhara N, Eguchi Y, Tsujimoto Y and Kuchino Y . 1997 Mol Cell Biol 17: 6736–6745
Krishnaraju K, Nguyen HQ, Liebermann DA and Hoffman B . 1995 Mol Cell Biol 15: 5499–5507
Liebermann DA and Hoffman B . 1994 Stem Cells Dayt 12: 352–369
Liebermann DA, Hoffman B and Steinman RA . 1995 Oncogene 11: 199–210
Liebermann DA and Hoffman-Liebermann B . 1989 Oncogene 4: 583–592
Lord KA, Abdollahi A, Hoffman-Liebermann B and Liebermann DA . 1990 Cell Growth Differ 1: 637–645
Lord KA, Abdollahi A, Hoffman-Liebermann B and Liebermann DA . 1993 Mol Cell Biol 13: 841–851
Meikrantz W and Schlegel R . 1995 J Cell Biochem 58: 160–174
Nesbit CE, Tersak JM and Prochownik EV . 1999 Oncogene 18: 3004–3016
Oltvai ZN and Korsmeyer SJ . 1994 Cell 79: 189–192
Oltvai ZN, Milliman CL and Korsmeyer SJ . 1993 Cell 74: 609–619
Packham G and Cleveland JL . 1995 Biochim Biophys Acta 1242: 11–28
Pear W, Nolan G, Scott M and Baltimore D . 1993 Proc Natl Acad Sci USA 90: 8392–8396
Pellicer A, Wigler M, Axel R and Silverstein S . 1978 Cell 14: 133–141
Peter M and Herskowitz I . 1994 Cell 79: 181–184
Prendergast GC . 1999 Oncogene 18: 2967–2987
Schmidt EV . 1999 Oncogene 18: 2988–2996
Selvakumaran M, Liebermann D and Hoffman-Liebermann B . 1993 Blood 81: 2257–2262
Selvakumaran M, Liebermann DA and Hoffman-Liebermann B . 1992 Mol Cell Biol 12: 2493–2500
Sherr CJ . 1996 Science 274: 1672–1677
Shi Y, Glynn JM, Guilbert LJ, Cotter TG, Bissonnette RP and Green DR . 1992 Science 257: 212–214
Spencer CA and Groudine M . 1991 Adv Cancer Res 56: 1–48
Tsujimoto Y and Croce CM . 1986 Proc Natl Acad Sci USA 83: 5214–5218
Wang R, Brunner T, Zhang L and Shi Y . 1998 Oncogene 17: 1503–1508
Ymer S, Tucker WQ, Sanderson CJ, Hapel AJ, Campbell HD and Young IG . 1985 Nature 317: 255–258
Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A and Oren M . 1991 Nature 352: 345–347
Zamzami N, Brenner C, Marzo I, Susin SA and Kroemer G . 1998 Oncogene 16: 2265–2282
Acknowledgements
This work was supported by National Institute of Health grant IROI CA81168 to B Hoffman.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Amanullah, A., Liebermann, D. & Hoffman, B. p53-independent apoptosis associated with c-Myc-mediated block in myeloid cell differentiation. Oncogene 19, 2967–2977 (2000). https://doi.org/10.1038/sj.onc.1203638
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1203638
Keywords
This article is cited by
-
Jungermannenone A and B induce ROS- and cell cycle-dependent apoptosis in prostate cancer cells in vitro
Acta Pharmacologica Sinica (2016)
-
Apoptotic signaling by c-MYC
Oncogene (2008)
-
Phosphatidylinositol 3-kinase/Akt signaling mediates interleukin-6 protection against p53-induced apoptosis in M1 myeloid leukemic cells
Oncogene (2007)
-
p53 is a regulator of macrophage differentiation
Cell Death & Differentiation (2004)
-
p19ARF directly and differentially controls the functions of c-Myc independently of p53
Nature (2004)